期刊文献+

血小板抗体检测在成分血输注中的临床意义 被引量:8

Clinical significance of platelet antibodies detection in blood component transfusion
在线阅读 下载PDF
导出
摘要 目的观察血小板抗体检测阴性和阳性患者血小板输注的临床治疗效果,探讨其相关的临床意义。方法收集2013年1~6月该院血小板抗体检测的病例60例。血小板抗体检测使用固相凝集法。结果 60例血小板输注患者共检测到血小板抗体26例,阳性率为43.3%,其中白血病阳性率为44.4%,再生障碍性贫血阳性率为41.6%,骨髓增生异常综合征阳性率为37.5%,恶性肿瘤阳性率为45.5%,各类疾病之间差异无显著性(P〉0.05)。血小板输注次数〈3次、3~8次和〉8次的患者血小板抗体的阳性率分别为23.8%、46.7%和77.8%,各组之间差异具有显著性(P〈0.05)。血小板抗体阴性和阳性患者血小板输注无效率分别为20.6%和69.2%,抗体阴性组显著低于阳性组(P〈0.01)。血小板抗体阴性患者血小板输注后1 h和24 h CCI值分别为(8.12±1.24)×109/L和(5.03±0.74)×109/L,均显著高于阳性组的(6.77±0.81)×109/L和(3.93±0.61)×109/L(P〉0.05)。结论血小板抗体阳性的患者具有较高的血小板无效输注发生率,相容性血小板配型试验是预防免疫性血小板无效输注的有效方法。 【Objective】To detect platelet antibodies in blood component transfusion and explore its clinical significance.【Methods】60 cases of patients received platelet transfusion were enrolled in this study. Platelet antibodies weredetermined by solid-phase agglutination.【Results】26 cases platelet antibodies were detected in 60 cases of patients with platelet transfusion with a positive rate of 43.3%. The positive rate was 44.4%, 41.6%, 37.5%, 45.5% in leukemia, aplastic anemia, myelodysplastic syndrome, and malignant tumor. There was no significant difference among various diseases(P 0.05). The positive rates of platelet antibody were 23.8%, 46.7% and 77.8% in platelet transfusions 3 times, 3-8 times, and 8 times group, respectively. There was no significant difference among various group(P 0.05). The rate of platelet transfusion refractoriness was 20.6% and 69.2% in antibody negative and positive group. Antibody-negative group was significantly lower than the positive group(P 0.01). The CCI values in platelet antibody-negative patients after 1h and 24 h CCI values were(8.12±1.24)×109/L and(5.03±0.74)×109/L, which were significantly higher than that of(6.77±0.81)×109/L and(3.93±0.61)×109/L in platelet antibody-positive group(P 0.05).【Conclusion】Platelet antibody-positive patients had a higher incidence of platelet transfusion refractoriness, platelet compatibility test was an effective way to prevent platelet transfusion refractoriness.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2014年第4期80-83,共4页 China Journal of Modern Medicine
关键词 血小板抗体 血小板无效输注 platelet antibody platelet transfusion refractoriness
  • 相关文献

参考文献10

二级参考文献42

  • 1张伟东,肖露露,叶欣,易燕,陈澍英.随机血小板输注无效患者的HLA抗体分析[J].广东医学,2004,25(7):799-800. 被引量:10
  • 2张洪淼,徐敏,王春香.148例输血患者HLA抗体筛查及临床应用[J].浙江预防医学,2005,17(3):69-69. 被引量:9
  • 3骆群,刘景汉.输血引起的免疫排斥、耐受与抑制[J].临床输血与检验,2005,7(2):152-154. 被引量:12
  • 4章旭,李剑平,迟立平,徐玉现,刘显智.基于PCR-SSP技术的HLA-A、B、CW、DRB1位点直接高分辨分型方法的应用[J].中国输血杂志,2006,19(5):399-400. 被引量:1
  • 5Heuer L, Blumenberg D. Management of bleeding in multi-trans- fused patient with positive HLA class I allo-antibodies and throm- bocytopenia associated with platelet dysfunction refractory to trans- fusion of cross-matched platelets. Blood Coagul Fibrinolysis,2005, 16(4) :287-290.
  • 6Vassallo RR. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients, Immuno- hematology. 2009,25 (3) : 119-124.
  • 7Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haema- tol.2008.142 ( 3 ) : 348 -360.
  • 8Fabris F,Soini B,Sartori R,et al. Clinical and laboratory factors that affect the post-transfusion platelet increment. Transfus Sei, 2000.23( 1 ) :63-68.
  • 9Davoren A, McParland P, C Rowley J, et al. Antenatal screening for human platelet antigen 21 a:results of a prospective study at a large maternity hospital in Ireland. B JOG,2003,110 ( 5 ) :492 -496.
  • 10胡丽华.临床血液检验[M].北京:中国医药科技出版社,2004:118-119,274-275.

共引文献94

同被引文献63

  • 1吕蕾,杨丽红.血小板输注在血液病中的治疗技巧与护理[J].现代中西医结合杂志,2004,13(19):2616-2616. 被引量:1
  • 2毕重丽.鼻出血填塞期病人的舒适护理[J].护理实践与研究,2008,5(1):30-31. 被引量:8
  • 3HOD E, SCHWARTZ J. Platelet transfusion refractoriness[ J]. Br J Haematol, 2008, 142 (3) : 348 - 360.
  • 4HOLBRO A, INFANTI L, SIGLE J, et al. Platelet transfusion: basic aspects[J]. Swiss Med Wkly, 2013, 143: w13885.
  • 5QUAGLIETYA A, NICOLUCCI A, ACCORSI P, et al. Survey of current practice for monitoring and management of platelet refracto- riness in Italy [ J ]. Transfus Apher Sci, 2012, 47 ( 3 ): 271 - 276.
  • 6ASTER R H, BOUGIE D W. Drug - induced immune thrombocy- topenia[ J. N Engl J Med, 2007, 357(6) : 580 -587.
  • 7SEMPLE J W, ASLAM R, KIM M, et al. Platelet -bound lipopo- lysaeeharide enhances Fc receptor - mediated phagocytosis of IgG - opsonized platelets[ J]. Blood, 2007, 109 ( 11 ) : 4803 - 4805.
  • 8TINMOUTH A T, SEMPLE E, SHEHATA N, et al. Platelet im- munopathology and therapy: a Canadian Blood Services Research and Development Symposium [ J ]. Transfus Med Rev, 2006, 20(4) : 294 -314.
  • 9PAVENSKI K, REBULLA P, DUQUESNOY R, et al. Efficacy of HLA - matched platelet transfusions for patients with hypoprolifera- rive thrombocytopenia: a systematic review [ J ]. Transfusion, 2013, 53 (10) : 2230 - 2242.
  • 10AGARWAL N, CHATI'ERJEE K, SEN A, et al. Prevalence of platelet reactive antibodies in patient's refractory to platelet trans- fusions[J]. Asian J Transfus Sci, 2014, 8(2) : 126 -127.

引证文献8

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部